Cargando…

Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study

Polymyositis (PM) and dermatomyositis (DM) are autoimmune-mediated multisystemic myopathies, characterized mainly by proximal muscle weakness. A connection between epilepsy and PM/DM has not been reported previously. Our study aim is to evaluate this association. A case–control study was conducted,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nissan, Ella, Watad, Abdulla, Cohen, Arnon D., Sharif, Kassem, Nissan, Johnatan, Amital, Howard, Shovman, Ora, Bragazzi, Nicola Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068784/
https://www.ncbi.nlm.nih.gov/pubmed/33920065
http://dx.doi.org/10.3390/ijerph18083983
_version_ 1783683083756634112
author Nissan, Ella
Watad, Abdulla
Cohen, Arnon D.
Sharif, Kassem
Nissan, Johnatan
Amital, Howard
Shovman, Ora
Bragazzi, Nicola Luigi
author_facet Nissan, Ella
Watad, Abdulla
Cohen, Arnon D.
Sharif, Kassem
Nissan, Johnatan
Amital, Howard
Shovman, Ora
Bragazzi, Nicola Luigi
author_sort Nissan, Ella
collection PubMed
description Polymyositis (PM) and dermatomyositis (DM) are autoimmune-mediated multisystemic myopathies, characterized mainly by proximal muscle weakness. A connection between epilepsy and PM/DM has not been reported previously. Our study aim is to evaluate this association. A case–control study was conducted, enrolling a total of 12,278 patients with 2085 cases (17.0%) and 10,193 subjects in the control group (83.0%). Student’s t-test was used to evaluate continuous variables, while the chi-square test was applied for the distribution of categorical variables. Log-rank test, Kaplan–Meier curves and multivariate Cox proportional hazards method were performed for the analysis regarding survival. Of the studied 2085 cases, 1475 subjects (70.7%) were diagnosed with DM, and 610 patients (29.3%) with PM. Participants enrolled as cases had a significantly higher rate of epilepsy (n = 48 [2.3%]) as compared to controls (n = 141 [1.4%], p < 0.0005). Using multivariable logistic regression analysis, PM was found only to be significantly associated with epilepsy (OR 2.2 [95%CI 1.36 to 3.55], p = 0.0014), whereas a non-significant positive trend was noted in DM (OR 1.51 [95%CI 0.99 to 2.30], p = 0.0547). Our data suggest that PM is associated with a higher rate of epilepsy compared to controls. Physicians should be aware of this comorbidity in patients with immune-mediated myopathies.
format Online
Article
Text
id pubmed-8068784
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80687842021-04-26 Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study Nissan, Ella Watad, Abdulla Cohen, Arnon D. Sharif, Kassem Nissan, Johnatan Amital, Howard Shovman, Ora Bragazzi, Nicola Luigi Int J Environ Res Public Health Article Polymyositis (PM) and dermatomyositis (DM) are autoimmune-mediated multisystemic myopathies, characterized mainly by proximal muscle weakness. A connection between epilepsy and PM/DM has not been reported previously. Our study aim is to evaluate this association. A case–control study was conducted, enrolling a total of 12,278 patients with 2085 cases (17.0%) and 10,193 subjects in the control group (83.0%). Student’s t-test was used to evaluate continuous variables, while the chi-square test was applied for the distribution of categorical variables. Log-rank test, Kaplan–Meier curves and multivariate Cox proportional hazards method were performed for the analysis regarding survival. Of the studied 2085 cases, 1475 subjects (70.7%) were diagnosed with DM, and 610 patients (29.3%) with PM. Participants enrolled as cases had a significantly higher rate of epilepsy (n = 48 [2.3%]) as compared to controls (n = 141 [1.4%], p < 0.0005). Using multivariable logistic regression analysis, PM was found only to be significantly associated with epilepsy (OR 2.2 [95%CI 1.36 to 3.55], p = 0.0014), whereas a non-significant positive trend was noted in DM (OR 1.51 [95%CI 0.99 to 2.30], p = 0.0547). Our data suggest that PM is associated with a higher rate of epilepsy compared to controls. Physicians should be aware of this comorbidity in patients with immune-mediated myopathies. MDPI 2021-04-10 /pmc/articles/PMC8068784/ /pubmed/33920065 http://dx.doi.org/10.3390/ijerph18083983 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nissan, Ella
Watad, Abdulla
Cohen, Arnon D.
Sharif, Kassem
Nissan, Johnatan
Amital, Howard
Shovman, Ora
Bragazzi, Nicola Luigi
Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study
title Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study
title_full Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study
title_fullStr Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study
title_full_unstemmed Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study
title_short Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis—A Cross-Sectional Study
title_sort epilepsy as a comorbidity in polymyositis and dermatomyositis—a cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068784/
https://www.ncbi.nlm.nih.gov/pubmed/33920065
http://dx.doi.org/10.3390/ijerph18083983
work_keys_str_mv AT nissanella epilepsyasacomorbidityinpolymyositisanddermatomyositisacrosssectionalstudy
AT watadabdulla epilepsyasacomorbidityinpolymyositisanddermatomyositisacrosssectionalstudy
AT cohenarnond epilepsyasacomorbidityinpolymyositisanddermatomyositisacrosssectionalstudy
AT sharifkassem epilepsyasacomorbidityinpolymyositisanddermatomyositisacrosssectionalstudy
AT nissanjohnatan epilepsyasacomorbidityinpolymyositisanddermatomyositisacrosssectionalstudy
AT amitalhoward epilepsyasacomorbidityinpolymyositisanddermatomyositisacrosssectionalstudy
AT shovmanora epilepsyasacomorbidityinpolymyositisanddermatomyositisacrosssectionalstudy
AT bragazzinicolaluigi epilepsyasacomorbidityinpolymyositisanddermatomyositisacrosssectionalstudy